During the last session, Vaxxinity Inc. (NASDAQ:VAXX)’s traded shares were 1.19 million. At the end of the trading day, the stock’s price was $1.94, reflecting an intraday loss of -7.18% or -$0.15. The 52-week high for the VAXX share is $22.77, that puts it down -1073.71 from that peak though still a striking 4.12% gain since the share price plummeted to a 52-week low of $1.86. The company’s market capitalization is $239.71M, and the average trade volume was 1.02 million shares over the past three months.
Vaxxinity Inc. (VAXX) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.00. VAXX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.53.
Vaxxinity Inc. (NASDAQ:VAXX) trade information
Vaxxinity Inc. (VAXX) registered a -7.18% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.18% in intraday trading to $1.94 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is -17.80%, and it has moved by -56.11% in 30 days.
The consensus price target of analysts on Wall Street is $15.00, which implies an increase of 87.07% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $18.00 respectively. As a result, VAXX is trading at a discount of -827.84% off the target high and -518.56% off the low.
Vaxxinity Inc. (VAXX) estimates and forecasts
Statistics show that Vaxxinity Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Vaxxinity Inc. (VAXX) shares have gone down -70.43% during the last six months, with a year-to-date growth rate more than the industry average at 34.08% against 0.60. In the rating firms’ projections, revenue will increase 797.70% compared to the previous financial year.
While earnings are projected to return -241.60% in 2022.
Vaxxinity Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vaxxinity Inc. (NASDAQ:VAXX)’s Major holders
Vaxxinity Inc. insiders own 106.98% of total outstanding shares while institutional holders control 17.71%, with the float percentage being -253.73%. Prime Movers Lab, LLC is the largest shareholder of the company, while 16 institutions own stock in it. As of Dec 30, 2021, the company held over 18.03 million shares (or 16.10% of all shares), a total value of $101.13 million in shares.
The next largest institutional holding, with 18.03 million shares, is of Prime Movers Lab, LLC’s that is approximately 16.08% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $101.13 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vaxxinity Inc. (VAXX) shares are Fidelity NASDAQ Composite Index Fund and ETF Managers Tr-ETFMG Treatments, Testing and Advancements ETF. Data provided on Feb 27, 2022 indicates that Fidelity NASDAQ Composite Index Fund owns about 68096.0 shares. This amounts to just over 0.06 percent of the company’s overall shares, with a $0.34 million market value. The same data shows that the other fund manager holds slightly less at 36881.0, or about 0.03% of the stock, which is worth about $0.22 million.